Skip to main content
Premium Trial:

Request an Annual Quote

Centogene Receives Noncompliance Notice From Nasdaq Over Market Value of Shares

NEW YORK – Centogene said on Wednesday afternoon that it was notified by the Nasdaq on June 8 that it no longer complies with the minimum market value of publicly held shares (MVPHS) for continued listing on the Nasdaq Global Market.

Under the listing rule, a company must maintain a minimum MVPHS of $15 million, a requirement that Centogene has not met for 30 consecutive business days, from April 26 to June 7, triggering the notification.

The Rostock, Germany-based company now has until Dec. 5 to regain compliance by having its MVPHS close at $15 million or more for at least 10 consecutive business days.

Centogene received a separate noncompliance notice from Nasdaq in April because the closing bid price of its common shares had fallen below the minimum of $1.00 for 30 consecutive business days. It has until Oct. 23 to regain compliance with that requirement by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.

In early Thursday afternoon trading, Centogene's shares were down 4 percent at $.78.

The Scan

Cystatin C Plays Role in Immunosuppression, Cancer Immunotherapy Failure, Study Finds

A study in Cell Genomics provides insight into how glucocorticoids can lead to cancer immunotherapy failure via cystatin C production.

Aging, Species Lifespan Gene Expression Signatures Overlap

An Osaka Metropolitan University team reports in Nucleic Acids Research that transcriptional signatures of aging and maximum lifespan have similarities.

Splicing Subgroup Provides Protocols for Evaluating Splicing Variant Data

The group presents their approach on how to apply evidence codes to splicing predictions and other data in the American Journal of Human Genetics.

Single-Cell Transcriptomic Atlas of Mouse Cochlea to Aid Treatment Development

Researchers in PNAS conducted single-cell and single-nuclear sequencing of about 120,000 cells at three key timepoints in cochlear development to generate a transcriptomic atlas.